7
May
2024

Zhejiang Langhua Pharmaceutical Co., ltd

Exhibitor at CPHI North America 2024 stand 1530
About Us

Langhua Pharma, an FDA, WHO, EDQM, ANVISA and NMPA approved manufacturer in China. It produces APIs, intermediates and delivers CDMO projects with Robust GMP and Strong EHS support. 
It is also experienced in filing in the regulated markets. New products like Cinacalcet HCl, Apremilast, Eltrombopag Diolamine,Tedizolid Phosphate can work with customers for registration.    

  • CN
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
Contact info
Event information
CPHI North America 2024
  • 07 May 2024 - 09 May 2024
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 1530

Products Featured at CPHI North America 2024

  • Spironolactone

    Product Spironolactone

    cardiovascular system drugs CEP and USDMF registered
  • Enrofloxacin

    Product Enrofloxacin

    Third generation Quinolones antibacterial products, veterinary use CEP and USDMF registered
  • Levofloxacin Hemihydrate

    Product Levofloxacin Hemihydrate

    Quinolones antibacterial product, anti-infective CEP , USDMF registered
  • Ciprofloxacin Hydrochloride

    Product Ciprofloxacin Hydrochloride

    Wide-range antibacterial
  • Canrenone

    Product Canrenone

    Intermediate grade: Assay: NLT 90%; NLT 97%. 
    API grade

Zhejiang Langhua Pharmaceutical Co., ltd Resources (1)

  • Video Applications of Green Chemistry in API Production

    This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Green Chemistry Overview Introduction to Green Chemistry- Twelve Principles and Examples Green Chemistry via Continuous Flow Advantages and Disadvantages Continuous flow reactors Continuous flow chemistry at Langhua